Back to results
US 2014/0349980 A1Published application
Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
OwnerAchim Schäfflerinventor
Life of this patent
Estimating the term…
Abstract
The present invention refers to the treatment of a patient suffering from rheumatoid arthritis by showing a reduction in signs and symptoms, a major or complete clinical response (remission) or even prevention of structural damages to the joints by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof.
Claims10
1-47. (canceled)
A method of administering prednisone to a patient having rheumatoid arthritis with a pain level of >50-70 mm on a 100 mm self reported visual analogue scale for pain comprising
- administering an oral dosage form comprising an initial dosage of 1, 2, 5, or 10 mg of prednisone, to the patient once daily at or before bedtime, wherein the oral dosage form is administered with food,
- determining the patient's clinical response to said administration, and
- if said patient has a satisfactory clinical response, the method further comprises administering a maintenance dosage that is less than the initial dosage until a dosage of prednisone which will maintain a satisfactory clinical response is reached, or
- if said patient does not have a satisfactory clinical response, the method further comprises administering an increased dosage that is more than the initial dosage until a satisfactory clinical response is determined,
- wherein release of the prednisone from the oral dosage form is delayed for a time period (tlag) of 2-10 hours after administration of the oral dosage form.
2 more elements
Dependencies are inferred from the claim text.